If one adenoviral vaccine is linked with blood clots, it doesn’t mean all vaccines in this family will have that same effect. But it's definitely worth health authorities assessing the data.
Academic rigor, journalistic flair
Articles on Adenovirus
Displaying all articles
AstraZeneca just announced results from its US-based trial. It found the vaccine to be 79% effective and safe for use, despite recent concerns around reports of blood clots.
The Johnson & Johnson vaccine is different from the Moderna and Pfizer vaccines in a few important ways that could make it a huge help to global vaccination efforts.
Under pressure to develop a coronavirus vaccine, researchers have turned to protein synthesis, genetics and hybrid viruses. It is likely a mix of these approaches will be used to fight the coronavirus.
Getting rid of this scourge is nothing to be sneezed at.
Top contributors
-
Associate Professor of Biology, Rochester Institute of Technology
-
Professor of Immunology and Infection and Head of Research of the School of Applied Sciences, Edinburgh Napier University
-
Professor, Abell Chair in Synthetic Biology, Colorado State University
-
Vice-Chancellor's Research Fellow, School of Health and Biomedical Sciences, RMIT University
